Cypherpunk Reports Q2 Net Profit of $39.4 Million

Cypherpunk Technologies achieved a net profit of $39.4 million in the second quarter, reversing a loss of $16.6 million in the same period last year. Despite an operating loss of $4.7 million, the company realized $46 million in unrealized gains from its Zcash treasury. As of the end of June, the company valued its $129.4 million position on its balance sheet at a price of $400.09 per ZEC. On August 11, Cypherpunk reported holding 323,394.38 Zcash, with an average purchase price of $341.83, representing approximately 1.92% of the circulating supply. The company incurred $200,000 in research and development expenses, while general and administrative expenses totaled $4.5 million. As of June 30, the company had $7.6 million in cash and cash equivalents, separate from the ZEC balance classified as digital asset receivables. Meanwhile, the company's wholly-owned biotechnology subsidiary, Leap Therapeutics, initiated a process to seek resources to advance sirexatamab to Phase 3 development, which may include independent financing or transactions with pharmaceutical companies, but there is no guarantee that this will be completed.